As with chil­dren stud­ies, Su­per­nus AD­HD drug shows fast on­set of ac­tion in ado­les­cents

Pos­i­tive piv­otal da­ta on Su­per­nus’ $SUPN AD­HD drug in chil­dren gave in­vestors pause ear­li­er this month be­cause of the lack of dose re­sponse at the high­er 400 mg dose, which weighed on the shares. On Thurs­day, the drug de­vel­op­er fol­lowed up with large­ly sim­i­lar Phase III da­ta from an ado­les­cent study, but the drug’s swift on­set of ac­tion, as seen in pre­vi­ous tri­als with chil­dren, may be a key dif­fer­en­tia­tor from ex­ist­ing AD­HD non-stim­u­lant med­ica­tions.

Two dos­es (200 mg/400 mg) of the drug, SPN-812, were test­ed against a place­bo in the 310-pa­tient ado­les­cent study P302. At week 6, pa­tients re­ceiv­ing SPN-812 200 mg and 400 mg had a -16.0 point change (p=0.0232) and a -16.5 point change (p=0.0091) on an AD­HD rat­ing scale, ver­sus -11.4 for those on the place­bo — meet­ing the main goal of the study. Over­all, pa­tients re­ceiv­ing 200 mg and 400 mg had an ef­fect size of 0.47 and 0.50, re­spec­tive­ly. Sig­nif­i­cant­ly, the high­er dose start­ed to work as soon as the first week, the com­pa­ny said.

Jack Khat­tar

“These da­ta fur­ther re­in­force the ef­fec­tive­ness of SPN-812 in pa­tients with AD­HD…with a fa­vor­able safe­ty and tol­er­a­bil­i­ty pro­file,” said CEO Jack Khat­tar in a state­ment. “We now have pos­i­tive da­ta prov­ing the ef­fi­ca­cy and safe­ty of SPN-812 in all AD­HD pa­tient pop­u­la­tions; pos­i­tive Phase III da­ta in chil­dren 6-11 years old and ado­les­cents 12-17 years old, and pos­i­tive Phase IIa da­ta in adults.”

An­oth­er Phase III study (P304) in ado­les­cents is ex­pect­ed to read out in the first quar­ter of 2019. But buoyed by the da­ta so far, Su­per­nus ex­pects to sub­mit a mar­ket­ing ap­pli­ca­tion by the end of the first quar­ter of 2019 and to launch — pend­ing FDA ap­proval — in the sec­ond half of 2020, it said on Thurs­day. The com­pa­ny’s shares edged up about 2.5% be­fore the bell.

In the first week of De­cem­ber, twin stud­ies eval­u­at­ing the ex­per­i­men­tal non-stim­u­lant drug in chil­dren showed sim­i­lar ef­fect sizes. In the P301 study, the 100 mg and 200 mg demon­strat­ed an ef­fect size of 0.54 and 0.57, re­spec­tive­ly. In the P303 tri­al, pa­tients re­ceiv­ing 200 mg and 400 mg had an ef­fect size of 0.46 and 0.49. Three out of the four dos­es were ob­served to have start­ed work­ing in week 1. But the com­pa­ny’s stock fell be­cause of the lack of dose-re­sponse seen with the high­er 400 mg dose, and wor­ries that the drug may have not per­formed well enough to dif­fer­en­ti­ate it­self from ex­ist­ing AD­HD drugs such as Lil­ly’s Stat­tera and Shire’s In­tu­niv.

Lil­ly’s $LLY Strat­tera — which achieved an ef­fect size of 0.4 to 0.6 in tri­als — was the first non-stim­u­lant med­ica­tion ap­proved for AD­HD, but it can take more than 6 weeks to start work­ing. Last year it went gener­ic, and is used for both chil­dren and ado­les­cents.

In a note ear­li­er this month, Jef­feries’ David Stein­berg sug­gest­ed that the over­all pro­file of SPN-812 was favourable. If ap­proved, it is set to reap peak sales of $400 mil­lion, he said.

Tesla and SpaceX founder Elon Musk gestures to the audience after being recognized by President Trump following the successful launch of a Falcon 9 rocket at the Kennedy Space Center. (via Getty Images)

Tes­la chief Elon Musk teams up with Covid-19 play­er Cure­Vac to build 'R­NA mi­cro­fac­to­ries'

Elon Musk has joined the global tech crusade now underway to revolutionize vaccine manufacturing — now aimed at delivering billions of doses of a new mRNA vaccine to fight Covid-19. And he’s cutting right to the front.

In a late-night tweet Wednesday, the Tesla chief announced:

Tesla, as a side project, is building RNA microfactories for CureVac & possibly others.

That’s not a lot to go on. But the tweet comes a year after Tesla’s German division in Grohmann and CureVac filed a patent on a “bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing.” CureVac, in the meantime, has discussed a variety of plans to build microfactories that can speed up the whole process for a global supply chain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Elias Zerhouni (Photo by Vincent Isore/IP3/Getty Images)

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

Elias Zerhouni favors blunt talk, and in a recent discussion with NPR, the ex-Sanofi R&D and ex-NIH chief had some tough points to make regarding the pandemic response.

Rather than interpret them, I thought it would be best to provide snippets straight from the interview.

On the Trump administration response:

It was basically amateur hour. There is no central concept of operations for preparedness, for pandemics, period. This administration doesn’t want to or has no concept of what it takes to protect the American people and the world because it is codependent. You can’t close your borders and say, “OK, we’re going to be safe.” You’re not going to be able to do that in this world. So it’s a lack of vision, basically just a lack of understanding, of what it takes to protect the American people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.

The incidents are derailing plans to file for a near-term approval, which had been expected right about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (Regeneron)

UP­DAT­ED: Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

Typically, the commencement speech at Yorktown Central School District in Westchester — like most high schools — is an opportunity to encourage students to face the future with confidence and hope. Regeneron president and co-founder George Yancopoulos, though, went a different route.

In a fiery speech, the outspoken billionaire defended the police against the “prejudice and bias against law enforcement” that has erupted around the country in street protests from coast to coast. And for many who attended the commencement, Yancopoulos struck the wrong note at the wrong time, especially when he combatively challenged someone for interrupting his speech with a honk for “another act of cowardness.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

Pfizer and their partners at the mRNA specialist BioNTech have published the first glimpse of biomarker data from an early-stage study spotlighting the “robust immunogenicity” triggered by their Covid-19 vaccine, which is one of the leaders in the race to vanquish the global pandemic.

Researchers selected 45 healthy volunteers 18-55 years of age for the study. They were randomized to receive 2 doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, “a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD.” Their responses were compared against the effect of a natural, presumably protective defense offered by a regular infection.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

Over the past few years, different teams at a pair of US-based biotechs and in labs in Japan have labored to piece together a group of cancer drug programs, sharing a single corporate umbrella with research colleagues in Japan. But now their far-flung operations have been knit together into a single unit, creating a pipeline with 10 cancer drug development programs — going from early-stage right into Phase III — and a host of discovery projects managed by a collective staff of some 265 people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)

Pos­i­tive Covid-19 vac­cine da­ta? New mouse study? OWS in­clu­sion? Yep, but some­how, the usu­al tid­bits from In­ovio back­fire

You don’t go more than 40 years in biotech without ever getting a product to market unless you can learn the art of writing a promotional press release. And Inovio captures the prize in baiting the hook.

Tuesday morning Inovio, which has been struggling to get its Covid-19 vaccine lined up for mass manufacturing, put out a release that touched on virtually every hot button in pandemic PR.

There was, first and foremost, an interim snapshot of efficacy from their Phase I program for INO-4800.

Jan van de Winkel, Genmab CEO

Seat­tle Ge­net­ics, Gen­mab turn on TV for a high­light reel in cer­vi­cal can­cer — but a ri­val biotech promis­es a bet­ter show

Seattle Genetics $SGEN and their partners at Genmab $GMAB polished up some positive Phase II numbers for their antibody drug conjugate tisotumab vedotin — you can call it TV — for recurrent cervical cancer. And while they mapped out a shortcut to a potential quick approval, the big challenge for this team is being presented by a rival biotech which muscled its way into the spotlight for the same indication a year ago.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Dan Gold, MEI Pharma CEO

De­vel­op­ment part­ners at MEI, Helsinn dump a high-risk PhI­II AML study af­ter con­clud­ing it would fail sur­vival goal

Four years after Switzerland’s Helsinn put $25 million of cash on the table for an upfront and near-term milestone to take MEI Pharma’s drug pracinostat into a long-running Phase III trial for acute myeloid leukemia, the partners are walking away from a clinical pileup.

The drug — an HDAC inhibitor — failed to pass muster during a futility analysis, as researchers concluded that pracinostat combined with azacitidine wasn’t going to outperform the control group in the pivotal.